Phaseline

Companies › Newish Technology (Beijing)

Newish Technology (Beijing): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NWRD06
Glypican 3 (GPC3)-targeted DNA plasmid vaccine
GPC3Phase 2Hepatocellular Carcinoma (HCC)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07324304NWRD06Phase 2Hepatocellular Carcinoma (HCC)OncologyDec 2028

Targets

GPC3 (1)

Companies with the same targets

AstraZeneca Keymed Biosciences Co.Ltd Aptamer Sciences Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Zymeworks BC RayzeBio SOTIO Biotech Bayer BeOne Medicines

Companies built like this

BrainChild Bio TVAX Biomedical Lukas Biomedical RhoVac APS March Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.